Skip to content
Steglatro(ertugliflozin)
Segluromet, Steglatro, Steglujan (ertugliflozin) is a small molecule pharmaceutical. Ertugliflozin was first approved as Steglatro on 2017-12-19. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2. In addition, it is known to target sodium/glucose cotransporter 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Steglatro
Combinations
Segluromet, Steglujan
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ertugliflozin
Tradename
Company
Number
Date
Products
STEGLATROMerck Sharp & DohmeN-209803 RX2017-12-19
2 products, RLD, RS
Ertugliflozin
+
Metformin hydrochloride
Tradename
Company
Number
Date
Products
SEGLUROMETMerck Sharp & DohmeN-209806 RX2017-12-19
4 products, RLD, RS
Ertugliflozin
+
Sitagliptin phosphate
Tradename
Company
Number
Date
Products
STEGLUJANMerck Sharp & DohmeN-209805 RX2017-12-19
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
seglurometNew Drug Application2022-11-20
steglatroNew Drug Application2022-11-07
steglujanNew Drug Application2021-11-19
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
ERTUGLIFLOZIN, STEGLATRO, MSD SUB MERCK
2024-09-17M-275
ERTUGLIFLOZIN / METFORMIN HYDROCHLORIDE, SEGLUROMET, MSD SUB MERCK
2024-09-17M-275
ERTUGLIFLOZIN / SITAGLIPTIN PHOSPHATE, STEGLUJAN, MSD SUB MERCK
2024-09-17M-275
Patent Expiration
Patent
Expires
Flag
FDA Information
Ertugliflozin / Metformin Hydrochloride, Segluromet, Msd Sub Merck
93082042030-10-21DP
94399022030-10-21U-2214
Ertugliflozin / Sitagliptin Phosphate, Steglujan, Msd Sub Merck
94399012030-10-21U-2214
73267082026-11-24DS, DPU-2214
Ertugliflozin, Steglatro, Msd Sub Merck
80805802030-07-13DS, DPU-2214
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD23: Metformin and ertugliflozin
— A10BD24: Sitagliptin and ertugliflozin
— A10BK: Sodium-glucose co-transporter 2 (sglt2) inhibitors
— A10BK04: Ertugliflozin
HCPCS
No data
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E1183113—25
Heart failureD006333EFO_0003144I50—231—6
HypertensionD006973EFO_0000537I10—1—2—3
Diabetic nephropathiesD003928EFO_0000401———2—2
Diastolic heart failureD054144EFO_1000899I50.30———1—1
Liver cirrhosisD008103EFO_0001422K74.0———1—1
Fatty liverD005234———1—1
Body weight changesD001836———1—1
Glycemic controlD000085002———1—1
Waist circumferenceD055105EFO_0004342———1—1
Show 2 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Implantable defibrillatorsD017147EFO_0010674——1——1
Cardiac resynchronization therapyD058406——1——1
Left ventricular dysfunctionD018487——1——1
Mitral valve insufficiencyD008944HP_0001653——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2————2
Cardiovascular diseasesD002318EFO_0000319I981————1
Insulin resistanceD007333EFO_00026141————1
AtherosclerosisD050197EFO_0003914I25.11————1
Hepatic insufficiencyD0485501————1
Renal insufficiencyD051437HP_0000083N191————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameERTUGLIFLOZIN
INNertugliflozin
Description
Ertugliflozin is a diarylmethane.
Classification
Small molecule
Drug classphlorozin derivatives, phenolic glycosides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1
Identifiers
PDB—
CAS-ID1210344-57-2
RxCUI1992672
ChEMBL IDCHEMBL1770248
ChEBI ID—
PubChem CID44814423
DrugBankDB11827
UNII ID6C282481IP (ChemIDplus, GSRS)
Target
Agency Approved
SLC5A2
SLC5A2
Organism
Homo sapiens
Gene name
SLC5A2
Gene synonyms
SGLT2
NCBI Gene ID
6524
Protein name
sodium/glucose cotransporter 2
Protein synonyms
Low affinity sodium-glucose cotransporter, Na(+)/glucose cotransporter 2, solute carrier family 5 (sodium/glucose cotransporter), member 2, solute carrier family 5 (sodium/glucose transporter), member 2, Solute carrier family 5 member 2
Uniprot ID
P31639
Mouse ortholog
Slc5a2 (246787)
sodium/glucose cotransporter 2 (Q923I7)
Alternate
SLC5A1
SLC5A1
Organism
Homo sapiens
Gene name
SLC5A1
Gene synonyms
NAGT, SGLT1
NCBI Gene ID
6523
Protein name
sodium/glucose cotransporter 1
Protein synonyms
High affinity sodium-glucose cotransporter, Na+/glucose cotransporter 1, solute carrier family 5 (sodium/glucose cotransporter), member 1, Solute carrier family 5 member 1
Uniprot ID
P13866
Mouse ortholog
Slc5a1 (20537)
sodium/glucose cotransporter 1 (Q8C3K6)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,270 documents
View more details
Safety
Black-box Warning
Black-box warning for: Segluromet
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,679 adverse events reported
View more details